2020
Updates in staging and pathologic evaluation of esophageal carcinoma following neoadjuvant therapy
Zhang X, Jain D. Updates in staging and pathologic evaluation of esophageal carcinoma following neoadjuvant therapy. Annals Of The New York Academy Of Sciences 2020, 1482: 163-176. PMID: 32892349, DOI: 10.1111/nyas.14462.Peer-Reviewed Original ResearchConceptsNeoadjuvant therapyEsophageal cancerEsophageal carcinomaRecent American Joint CommitteePreoperative neoadjuvant therapyThorough pathologic assessmentTumor regression gradingAdvanced esophageal carcinomaAmerican Joint CommitteeCancer (AJCC) staging systemTumor regression gradeAccurate tumor stagingValuable prognostic informationRegression gradingSurgical resectionLymph nodesPathologic assessmentRegression gradeHistologic typePathologic evaluationResidual tumorPoor prognosisCell carcinomaGastrointestinal carcinomasStaging systemLiver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
Celli R, Saffo S, Kamili S, Wiese N, Hayden T, Taddei T, Jain D. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection. Archives Of Pathology & Laboratory Medicine 2020, 145: 419-427. PMID: 32810870, PMCID: PMC10960369, DOI: 10.5858/arpa.2020-0008-oa.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaHCC developmentChronic hepatitis C virus (HCV) infectionChronic viral hepatitis C infectionHepatitis C virus infectionViral hepatitis C infectionTissue polymerase chain reactionAntiviral agent therapyLiver histologic findingsLiver pathologic changesNon-SVR groupOccult HCV infectionPersistent liver inflammationSuccessful DAA therapyC virus infectionHepatitis C infectionSubset of patientsDegree of inflammationNumber of patientsPresence of virusDAA therapySVR patientsVirologic responseC infectionHCV infection
2016
Therapeutic Challenges of Hepatic Mucormycosis in Hematologic Malignancy: A Case Report and Review of the Literature
Bernardo RM, Gurung A, Jain D, Malinis MF. Therapeutic Challenges of Hepatic Mucormycosis in Hematologic Malignancy: A Case Report and Review of the Literature. American Journal Of Case Reports 2016, 17: 484-489. PMID: 27406045, PMCID: PMC4948661, DOI: 10.12659/ajcr.898480.Peer-Reviewed Case Reports and Technical NotesConceptsDual antifungal therapyAntifungal therapyHepatic mucormycosisSurgical resectionClinical presentationCase reportLiver lesionsIsolated hepatic mucormycosisTransplant-associated infectionsMultiple liver lesionsCombination antifungal therapyAcute myeloid leukemiaHigh mortality rateOptimal antifungal therapyGastrointestinal involvementInduction chemotherapyNeutropenic feverAbdominal painLymphoproliferative disordersTherapeutic challengeHematologic malignanciesCommon siteMyeloid leukemiaTreatment strategiesGastrointestinal tractVaried autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells
Monestime G, Borger DK, Kim J, Lopez G, Allgaeuer M, Jain D, Vortmeyer A, Wang HW, Sidransky E. Varied autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells. Molecular Genetics And Metabolism 2016, 118: 55-59. PMID: 26992326, DOI: 10.1016/j.ymgme.2016.02.008.Peer-Reviewed Original ResearchConceptsAutopsy findingsGaucher diseaseDose/durationEnzyme replacement therapySpleen statusPathological findingsReplacement therapyDisease burdenPathological studiesGaucher cellsPatientsHematological symptomsExtensive involvementTherapyParkinsonismDiseaseMultiple tissuesComplete absenceFindingsAutopsiesSymptomsPathologyBiomarkersCare
2011
Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer
Zeng H, Yu H, Lu L, Jain D, Kidd MS, Saif MW, Chanock SJ, Hartge P, Risch H. Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer. Pancreas 2011, 40: 657-663. PMID: 21487324, PMCID: PMC3116071, DOI: 10.1097/mpa.0b013e31821268d1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overATP Binding Cassette Transporter, Subfamily G, Member 2ATP-Binding Cassette TransportersCase-Control StudiesConnecticutDihydrouracil Dehydrogenase (NADP)FemaleGenetic MarkersGenetic VariationGenome-Wide Association StudyHumansMaleMiddle AgedNeoplasm ProteinsPancreatic NeoplasmsPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsSerpinsSurvival AnalysisTreatment OutcomeConceptsPancreatic cancerOverall survivalCancer survivalProportional hazards regression modelsSurvival of patientsPopulation-based studyPancreatic cancer survivalHazards regression modelsGerm-line genetic variationEvidence of associationClinical outcomesCancer patientsTreatment outcomesTreatment responseSignificant associationPatientsCancerPrevious genome-wide association study dataRadiotherapyPutative markerGenetic polymorphismsSurvivalDPYD geneChemotherapyEvidence of interaction
2009
HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin
Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W. HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin. Journal Of Clinical Gastroenterology 2009, 43: 477-481. PMID: 19142165, PMCID: PMC3715868, DOI: 10.1097/mcg.0b013e318180803a.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseHepatitis C virusCombination therapyRenal diseasePosttreatment rateSide effectsSerious adverse side effectsDose of ribavirinNon-ESRD patientsSafe therapeutic optionEarly virologic responseProspective observational studyMonths of treatmentStage renal diseaseCases of anemiaInitial response rateLength of treatmentInterferon α-2aAdverse side effectsPO weeklyVirologic responseESRD patientsHCV infectionESRD populationHCV response
2008
Adult nesidioblastosis. Clinicopathologic correlation between pre-operative selective arterial calcium stimulation studies and post-operative pathologic findings.
Kenney B, Tormey CA, Qin L, Sosa JA, Jain D, Neto A. Adult nesidioblastosis. Clinicopathologic correlation between pre-operative selective arterial calcium stimulation studies and post-operative pathologic findings. JOP Journal Of The Pancreas 2008, 9: 504-11. PMID: 18648143.Peer-Reviewed Original ResearchConceptsDifferential diagnosisDiffuse islet cell hyperplasiaPost-operative pathologic findingsMarked insulin releaseSevere hyperinsulinemic hypoglycemiaIslet cell hyperplasiaCase of nesidioblastosisIslet cell proliferationPancreatic ductal epitheliumRoutine diagnostic laboratoryFactitious hypoglycemiaRadiological findingsSevere hypoglycemiaSubtotal pancreatectomyPathologic findingsAdult nesidioblastosisCell hyperplasiaClinicopathologic correlationPancreatic segmentsDuctal epitheliumHyperinsulinemic hypoglycemiaCalcium challengeHistologic examinationLaboratory examinationsPartial pancreatectomy
2004
Rapid Progression of Autoimmune Hepatitis in the Background of Primary Sclerosing Cholangitis
Hong-Curtis J, Yeh M, Jain D, Lee JH. Rapid Progression of Autoimmune Hepatitis in the Background of Primary Sclerosing Cholangitis. Journal Of Clinical Gastroenterology 2004, 38: 906-909. PMID: 15492611, DOI: 10.1097/00004836-200411000-00015.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisAutoimmune hepatitisOverlap syndromeSclerosing cholangitisLiver diseaseHemolytic anemiaAIH/PSC overlap syndromePrompt recoveryDiagnosis of AIHPatient's prompt recoveryAutoimmune liver diseaseAutoimmune hemolytic anemiaProgressive liver failurePrimary biliary cirrhosisAcidophil bodiesAutoimmune cholangitisInterface hepatitisImmunosuppressive therapyBiliary cirrhosisLiver biopsyLiver failureLymphoplasmacytic infiltrateUlcerative colitisClinical symptomsLiver function